Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors ...Middle East

PR Newswire - News
Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study (NCT05431270) of PT199, an anti-CD73...

Hence then, the article about phanes therapeutics announces first patient dosed in phase 1 study of pt199 for advanced solid tumors was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors )

Apple Storegoogle play

Last updated :

Also on site :